Lei Jianping on January 3
The IPO of Auskang Biotechnology (Nantong) Co., Ltd. (hereinafter referred to as "Auscom Biotech") was terminated a few days ago, and Auscom Biotech was preparing to be listed on the Science and Technology Innovation Board, with the original plan to raise 3 billion yuan.
Among them, 550 million yuan will be used for the R&D and production project of Shanghai Aosikang conjugate drugs, 1.45 billion yuan will be used for the CDMO platform project of Shanghai Aosikang biopharmaceutical, and 1 billion yuan will be used to supplement working capital.
With an annual revenue of 450 million, he lost his cooperation with CanSino
Based on the forefront of biologics CMC, Auscom Biotech has worked closely with domestic and foreign institutions with its own complete, flexible and modular production process platform to rapidly improve its own innovation capabilities, and has served dozens of customers in the CDMO sector and more than 200 customers in the cell culture media sector.
In terms of media formulation, process development services, and CDMO service cooperation, Auscom Biotech has established agency or strategic cooperative relations with Asian multinational enterprises, and the company is also seeking more strategic partners.
According to the prospectus, the revenue of Auscom Biotechnology in 2019, 2020 and 2021 will be 87.136 million yuan, 210 million yuan and 451 million yuan respectively, the net profit will be -79.75 million yuan, -38.17 million yuan and 71.8686 million yuan respectively, and the net profit after deducting non-profits will be -86.13 million yuan, -47.735 million yuan and 46.41 million yuan respectively.
At the end of the reporting period, the book value of the company's accounts receivable was 29.0669 million yuan, 81.9397 million yuan and 160 million yuan respectively, accounting for 8.61%, 11.16% and 5.04% of the total assets respectively.
On January 13, 2022, due to the adjustment of vaccine production regulatory policies, CanSino terminated the contract for the entrusted production of adenovirus new crown vaccine stock solution to Auscom Biotech (other CDMO businesses of Auscom Biotech were not affected), and on January 28, 2022, the relevant content of the stock solution of the recombinant new coronavirus vaccine (adenovirus type 5 vector) entrusted to the production scope of Auscom Biologics was reduced.
After the termination of the entrusted production business of adenovirus new crown vaccine stock solution between Auscom Biologics and CanSino, Auscom Biotech has adjusted the production schedule in a timely manner and switched the production capacity originally used for the entrusted production of CanSino new crown vaccine stock solution to other customer projects, but the switching process requires production line cleaning, equipment commissioning and other work, and the production of new projects needs to follow the capacity ramp-up process of gradually increasing the operating load.
Hillhouse and Fosun are shareholders
In 2019, Auscom Biotech announced the completion of more than 300 million yuan in Series A financing, in July 2020, it announced the completion of 450 million yuan in Series B financing, and in March 2021, it announced the completion of more than 400 million yuan in Series C financing, which was jointly led by China State-owned Capital Venture Capital Fund (hereinafter referred to as "China Venture Capital Fund") and Hillhouse Venture Capital. Fosun's fund and a number of old shareholders jointly funded the completion.
In December 2021, Auscom announced the completion of a new round of financing of 1.5 billion yuan, led by shareholders Goldstone Investment and CDH Baifu, and followed by a number of well-known institutions.
Before the IPO, SHUN LUO indirectly controlled 18.07% of the shares through the personal shareholding platform Yuanyuan Biotech, and indirectly controlled 7.01% and 0.85% of the company's shares through the employee shareholding platforms Chengmai Jianshun and Auskang No. 1, respectively, and controlled a total of 25.93% of the company's shares.
SHUN LUO, Chinese NAME IS "LUO SHUN". Born in July 1962, he is an American citizen with permanent residency in China, and graduated from Virginia Tech University with a Ph.D. in molecular immunology. From August 1993 to September 1999, he served as the chief researcher of Serono, Switzerland, the chief scientist of Beckman Coulter, Inc. from September 1999 to August 2001, the chairman of Gene XP Biosciences from August 2001 to February 2003, and the R&D director of the R&D department of JRH Biosciences from February 2003 to September 2005.
From November LUO2005 to February 2008, SHUN served as Genentech in the United States Inc. served as the scientific director of the cell culture process R&D department of Amgen from March 2008 to June 2011, the chief executive officer of Gansu Wanzhou Jianshun Biotechnology Co., Ltd. from July 2011 to July 2014, the chairman and general manager of Gansu Jianshun since July 2014, and the chairman and general manager of Auscom Biotechnology since March 2017.
In addition, CICC Jiatai holds 8.27% of the shares, Chengmai Jianshun holds 7.01% of the shares, Changxia Jinshi holds 5.68% of the shares, Shanghai Lianyi holds 4.82% of the shares, Hillhouse Qianheng holds 4.21% of the shares, New Materials Fund holds 2.3% of the shares, CCB International holds 2.29% of the shares, Shenzhen Wing Loong holds 2.27% of the shares, Guangdong Wen's shares hold 2.25% of the shares, and Guofeng Dingjia holds 2.16% of the shares;
Shixin Biotech holds 2.03% of the shares, Yinglian Health holds 1.95% of the shares, OLM holds 1.87% of the shares, Qianrong Yingrun and Binghong Jiashi hold 1.81% of the shares, CDH Junyao holds 1.72% of the shares, Fosun Weishi and Fosun Weiying hold 1.44% of the shares respectively, Huaxu Investment holds 1.34% of the shares, Jiaxing Lianyi holds 1.21% of the shares, and Ren Jun Tianrun and Chenxi No. 8 hold 1.15% of the shares respectively.
———————————————
Lei Di was founded by Lei Jianping, a media person, if it is reprinted, please indicate the source.